Nivolumab (nivo) in combination with radiotherapy (RT) ± temozolomide (TMZ): Updated safety results from CheckMate 143 in pts with methylated or unmethylated newly diagnosed glioblastoma (GBM)

被引：0
|
作者：
Lim, M. [1 ]
Omuro, A. [2 ]
Vlahovic, G. [3 ]
Reardon, D. A. [4 ,5 ]
Sahebjam, S. [6 ]
Cloughesy, T. [7 ]
Baehring, J. [8 ]
Butowski, N. [9 ]
Potter, V. [10 ]
Zwirtes, R. [10 ]
Paliwal, P. [10 ]
Carleton, M. [10 ]
Sampson, J. [3 ]
Brandes, A. A. [11 ]
机构：
[1] Johns Hopkins Univ, Sch Med, Metastat Brain Tumor Ctr, Baltimore, MD USA
[2] Mem Sloan Kettering Canc Ctr, Neurol, 1275 York Ave, New York, NY 10021 USA
[3] Duke Univ, Med Ctr, Preston Robert Tisch Brain Tumor Ctr Duke, Durham, NC USA
[4] Dana Farber Canc Inst, Ctr Neurooncol, Boston, MA 02115 USA
[5] Harvard Univ, Sch Med, Boston, MA USA
[6] Univ S Florida, H Lee Moffitt Canc Ctr, Oncol, Tampa, FL 33682 USA
[7] Univ Calif Los Angeles, Neurol Oncol, Los Angeles, CA USA
[8] Yale Sch Med, Neurol, New Haven, CT USA
[9] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA
[10] Bristol Myers Squibb Co, Oncol, Princeton, NJ USA
[11] AUSL IRCCS Inst Neurol Sci, Neurol, Bologna, Italy
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3250
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Full enrollment results from an extended phase I, multicenter, open label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma (GBM).
    Mason, Warren P.
    Kesari, Santosh
    Stupp, Roger
    Aregawi, Dawit Gebremichael
    Piccioni, David Eric
    Roth, Patrick
    Desjardins, Annick
    Reich, Steven D.
    Casadebaig, Marie-Laure
    Elias, Ileana
    Winograd, Benjamin
    Levin, Nancy
    Bota, Daniela Annenelie
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [22] Efficacy and safety of bevacizumab (By) plus standard combination temozolomide (T) and radiotherapy (RT) in newly diagnosed glioblastoma: final results from AVAglio
    Chinot, O.
    Cloughesy, T.
    Henriksson, R.
    Saran, F.
    Mason, W.
    Nishikawa, R.
    Hilton, M.
    Abrey, L.
    Wick, W.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S774 - S775
  • [23] THE EFFECT OF TIMING OF RADIOTHERAPY (RT) IN PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM) RECEIVING TEMOZOLOMIDE (TMZ): AN ANALYSIS BASED ON THE UCSF EXPERIENCE
    Han, S. J.
    Rutledge, W. C.
    Molinaro, A. M.
    Chang, S.
    Clarke, J. L.
    Prados, M. D.
    Berger, M. S.
    Butowski, N. A.
    NEURO-ONCOLOGY, 2014, 16
  • [24] THE EFFECT OF DELAYING RADIOTHERAPY (RT) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM) RECEIVING TEMOZOLOMIDE (TMZ): A SECONDARY ANALYSIS BASED ON THE UCSF EXPERIENCE
    Butowski, Nicholas A.
    Polley, Mei-Yin C.
    Lamborn, Kathleen L.
    Chang, Susan
    Prados, Michael
    Clarke, Jennifer L.
    Huang, Kim
    Sneed, Patricia
    NEURO-ONCOLOGY, 2009, 11 (05) : 665 - 665
  • [25] Health-related quality of life (HRQL) in VERTU: A randomized phase II trial of veliparib (V), radiotherapy (RT), and temozolomide (TMZ) for newly diagnosed MGMT unmethylated (uMGMT) glioblastoma (GBM).
    Sim, Hao-Wen
    Barnes, Elizabeth
    Lwin, Zarnie
    Rosenthal, Mark
    Wheeler, Helen
    Koh, Eng-Siew
    Foote, Matthew C.
    Fisher, Lauren
    Leonard, Robyn
    Hall, Merryn
    Simes, John
    Khasraw, Mustafa
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [26] A RANDOMIZED PHASE 3 STUDY OF NIVOLUMAB OR PLACEBO COMBINED WITH RADIOTHERAPY PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WITH METHYLATED MGMT PROMOTER: CHECKMATE 548
    Weller, Michael
    Lim, Michael
    Idbaih, Ahmed
    Steinbach, Joachim
    Finocchiaro, Gaetano
    Raval, Raju
    Ashby, Lynn
    Ansstas, George
    Baehring, Joachim
    Taylor, Jennie
    Honnorat, Jerome
    Petrecca, Kevin
    De Vos, Filip
    Wick, Antje
    Sumrall, Ashley
    Roberts, Mustimbo
    Slepetis, Ruta
    Warad, Deepti
    Lee, Michelle
    Reardon, David
    Omuro, Antonio
    NEURO-ONCOLOGY, 2021, 23 : 55 - 56
  • [27] NRG BN002: SAFETY DATA FROM A PHASE I STUDY OF IPILIMUMAB (IPI), NIVOLUMAB (NIVO), AND THE COMBINATION FOR NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
    Gilbert, Mark
    Zhang, Peixin
    Sloan, Andrew
    Aldape, Kenneth
    Wu, Jing
    Rogers, Lisa
    Wen, Patrick
    Barani, Igor
    Iwamoto, Fabio
    Raval, Raju
    Voloshin, Alfredo
    de Groot, John
    Won, Minhee
    Mehta, Minesh P.
    NEURO-ONCOLOGY, 2018, 20 : 7 - 7
  • [28] Safety and efficacy of the addition of bevacizumab (BV) to temozolomide (TMZ) and radiation therapy (RT) followed by BV, TMZ, and irinotecan (CPT-11) for newly diagnosed glioblastoma multiforme (GBM)
    Vredenburgh, J. J.
    Desjardins, A.
    Reardon, D. A.
    Peters, K.
    Herndon, J. E., II
    Kirkpatrick, J.
    Gururangan, S.
    Bailey, L.
    Friedman, A. H.
    Friedman, H. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [29] Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group
    Stupp, R
    Mason, WP
    Van Den Bent, MJ
    Weller, M
    Fisher, B
    Taphoorn, M
    Brandes, AA
    Cairncross, G
    Lacombe, D
    Mirimanoff, RO
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 1S - 1S
  • [30] RADIOTHERAPY (RT) WITH CONCOMITANT AND ADJUVANT TEMOZOLOMIDE (TMZ) IN GLIOBLASTOMA MULTIFORME (GBM) - LONG TERM RESULTS FROM A SINGLE UNITED KINGDOM CENTRE
    Haylock, B.
    Husband, D.
    Shenoy, A.
    Wong, H.
    Brodbelt, A.
    Walker, C.
    RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S34 - S35
12345